Cardiac safety failures remain a top reason for drug attrition — and many stem from unreliable preclinical models. Ncyte® vCardiomyocytes are changing that.
Engineered for stability, consistency and large-scale production, Ncyte® vCardiomyocytes offer the functional performance needed for today’s high-throughput and regulatory-aligned safety studies. With validated compatibility across MEA, calcium flux and contractility assays, this human iPSC-derived platform helps researchers screen smarter, reduce revalidations and generate reproducible, CiPA-aligned data at scale.
Download our white paper to discover:
Whether you’re screening thousands of compounds or preparing for regulatory submission, you can’t afford inconsistency. Meet the scalable solution that supports confident, efficient testing.